2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139262A
    FNC-TP trisodium
    		Inhibitor
    FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. FNC-TP (trisodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    FNC-TP trisodium
  • HY-158329
    Alloc-DOX
    		Inhibitor 98.40%
    Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth.
    Alloc-DOX
  • HY-106233
    Tiviciclovir
    		Inhibitor
    Tiviciclovir (AM188) is an antiviral guanosine analog and a hepatitis B virus inhibitor.
    Tiviciclovir
  • HY-100029A
    Bay 41-4109 racemate
    		Inhibitor 98.92%
    BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
    Bay 41-4109 racemate
  • HY-16678
    Helioxanthin
    		99.76%
    Helioxanthin (ACH126447) has in vitro antiviral activity with an EC50 of 1 μM against HBV and is also active against flaviviruses.
    Helioxanthin
  • HY-N8153
    Glycosmisic acid
    		Inhibitor
    Glycosmisic acid, a natural compound, possesses anti-HBV activity.
    Glycosmisic acid
  • HY-16679
    Helioxanthin derivative 5-4-2
    		Inhibitor 99.80%
    Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.
    Helioxanthin derivative 5-4-2
  • HY-B1192R
    Estradiol benzoate (Standard)
    Estradiol benzoate (Standard) is the analytical standard of Estradiol benzoate. This product is intended for research and analytical applications. Estradiol benzoate (β-Estradiol 3-benzoate) is a HBx protein inhibitor and inhibits androgen and hepatitis B virus (HBV) transcription, replication. Estradiol benzoate shows antifertility effects, anti- Toxoplasma gondii activity and can improve memory behavior of Ovariectomy (Ovx) female mice.
    Estradiol benzoate (Standard)
  • HY-19447A
    Besifovir Dipivoxil maleate
    		Inhibitor
    Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies[2]
    Besifovir Dipivoxil maleate
  • HY-144319
    SHR5133
    		Inhibitor
    SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC50=26.6 nM).
    SHR5133
  • HY-139574
    Firzacorvir
    		Inhibitor
    Firzacorvir is a cyclic sulfamide compound and modulates HBV core protein. Firzacorvir has anti-HBV activity with EC50 < 1 μΜ.
    Firzacorvir
  • HY-147269
    Fosclevudine alafenamide
    		Inhibitor
    Fosclevudine alafenamide (Compound EIDD-02173) is an antiviral agent with an EC50 of 1.71 μM against HBV.
    Fosclevudine alafenamide
  • HY-B0250A
    Lamivudine salicylate
    		Inhibitor
    Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine salicylate
  • HY-P990924
    Libevitug
    HY-P990924 is an HBV-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).
    Libevitug
  • HY-159160
    HBV-IN-46
    		Inhibitor
    HBV-IN-46 (compound 1.6) is an active metabolite. HBV-IN-46 is a HBV S-antigen inhibitor, with an EC50 of 2.6 nM.
    HBV-IN-46
  • HY-N0680R
    Thiamine hydrochloride (Standard)
    		Inhibitor
    Thiamine (hydrochloride) (Standard) is the analytical standard of Thiamine (hydrochloride). This product is intended for research and analytical applications. Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.
    Thiamine hydrochloride (Standard)
  • HY-144320
    HBV-IN-17
    		Modulator
    HBV-IN-17 (compound 8) is a potent HBV capsid assembly modulator with an EC50 of 511 nM.
    HBV-IN-17
  • HY-145052
    HBV-IN-9
    		Inhibitor
    HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells). From patent WO2018001952A1, example 20.
    HBV-IN-9
  • HY-149815
    HBV-IN-33
    		Inhibitor
    HBV-IN-33 (C-49), a HBV inhibitor, notably suppresses HBV replication in HepAD38, HepG2-HBV1.3 and HepG2-NTCP cells.
    HBV-IN-33
  • HY-W654247
    Lamivudine-13C,d2
    Lamivudine-13C,d2 is the deuterium labeled and 13C-labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>13</sup>C,d<sub>2</sub>
Cat. No. Product Name / Synonyms Application Reactivity